Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

Magellan Stem Cell researchers have been honoured with a Research Publication of the Year Award by a prestigious international medical journal.The ...

Stablepharma Ltd is a high-growth biotechnology company based in the UK and Spain, with the mission to reduce reliance on the ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan (University of California, San Diego), Julio Rojas (UCSF) and ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

George Warren, PhD, Lead Author and Principal Scientist at Artelo, said, “We are excited to share the results on this novel target in psoriasis. Our findings demonstrate that ART26.12 has effects ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia ...